Table 2 Treatment outcomes for participants finishing follow-up
n (%) | ||||||
|---|---|---|---|---|---|---|
Benguela | Zaire | Lunda Sul | ||||
DPb | ASAQa | ALa | ASAQa | ALa | DPb | |
n = 85 | n = 91 | n = 94 | n = 90 | n = 91 | n = 89 | |
Treatment failure | 5 (6) | 1 (1) | 7 (7) | 16 (18) | 9 (10) | 0 |
Early treatment failure | 0 | 0 | 0 | 0 | 0 | 0 |
Late treatment failure | 5 (6) | 1 (1) | 7 (7) | 16 (18) | 9 (10) | 0 |
Recrudescence | 0 | 0 | 4 (4) | 5 (6) | 3 (3) | 0 |
Day 21 | 0 | 0 | 1 (1) | 5 (6) | 3 (3) | 0 |
Day 28 | 0 | 0 | 3 (3) | 0 | 0 | 0 |
Day 35 | 0 | – | – | – | – | 0 |
Day 42 | 0 | – | – | – | – | 0 |
Reinfection | 5 (6) | 1 (1) | 3 (3) | 11 (12) | 6 (7) | 0 |
Day 21 | 0 | 0 | 0 | 7 (8) | 2 (2) | 0 |
Day 28 | 0 | 1 (1) | 3 (3) | 4 (4) | 4 (4) | 0 |
Day 35 | 2 (2) | – | – | – | – | 0 |
Day 42 | 3 (4) | – | – | – | – | 0 |
Adequate clinical and parasitological response | 80 (94) | 90 (99) | 87 (93) | 74 (82) | 82 (90) | 89 (100) |